503A vs 503B Pharmacies: What the Difference Means for You in 2026
Key Takeaways
- 503A pharmacies compound patient-specific prescriptions — the traditional model. Legal for semaglutide with a valid Rx.
- 503B outsourcing facilities can compound in bulk without individual prescriptions — but only for drugs in shortage or under specific conditions
- 503B facilities are FDA-registered and inspected; 503A pharmacies are state-regulated
- For patients: the practical difference is which pharmacy your provider uses — both can produce quality products
- In 2026, 503A is the safer legal pathway for compounded semaglutide since the shortage ended
503A and 503B are the two legal frameworks for compounding in the U.S. The distinction matters because it determines whether a pharmacy can legally compound semaglutide in 2026 — and how much regulatory oversight applies.
Side-by-Side Comparison
| Feature | 503A (Traditional) | 503B (Outsourcing) |
|---|---|---|
| Legal basis | State pharmacy law + FDCA §503A | FDCA §503B (created 2013) |
| Prescription required? | Yes — individual, patient-specific | Not always — can distribute without Rx |
| FDA registration? | Not required (state-regulated) | Required — FDA-registered |
| FDA inspection? | Not routine (state boards inspect) | Regular FDA inspections |
| Bulk compounding? | Limited — must be patient-specific | Yes — can compound in advance |
| Semaglutide in 2026? | Legal with valid Rx | Restricted — shortage ended |
| Accreditations | PCAB, state license | FDA registration, cGMP-like standards |
What to Look For
503A: Check for active state pharmacy license + PCAB accreditation (voluntary but signals quality). Ask your provider which pharmacy compounds your medication.
503B: Verify FDA registration at FDA.gov. Check for recent inspection results.
Embody
GLP-1 · LeadCompounded injectable semaglutide. Established program, strong clinical support. Lead anchor provider.
Uses licensed 503A compounding pharmacy.
MadeMed
Inj. SemaCompounded injectable semaglutide. $119/mo or $89/mo on quarterly plan.
Compounded through licensed pharmacy.
Both 503A and 503B can produce quality compounded medications. In 2026, 503A is the clearer legal pathway for semaglutide. What matters most for patients: your provider uses a licensed, accredited pharmacy with proper quality controls, and your prescription is legitimate and patient-specific.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.